IMU News: Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf alloge - 11th Nov 2022, 9:00am

[annb0t]

Celularity, Inc.

SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, are pleased to announce that data from preclinical studies of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-deri...

>>> Read more: Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting